StoneX Group’s Karyopharm Therapeutics KPTI Stock Holding History

StoneX Group’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$25.2K	Buy	+17,019	New	+$69.6K	﹤0.01%	1713

Other funds holding KPTI

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Context Capital Management Lajolla, California $4.89B AUM 1.86% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Owl Creek Wealth Partners Denver, Colorado $355M AUM

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

StoneX Group's KPTI Position: Q3 2026 in Review

StoneX Group opened a new position in Karyopharm Therapeutics (KPTI) in Q3 2026: 17,019 shares worth $25.2K. The stake represents ﹤0.01% of the portfolio and ranks #1713 among its holdings.

18 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

StoneX Group held 17,019 shares of Karyopharm Therapeutics worth $25.2K as of Q3 2026.
Karyopharm Therapeutics was a new StoneX Group position in Q3 2026.
Karyopharm Therapeutics made up ﹤0.01% of StoneX Group's portfolio in Q3 2026, its #1713 holding.
18 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.